Literature Review : Perkembangan Pengobatan Kemoterapi Kanker Payudara
-
Keywords:
Keywords: Breast Cancer, Chemotherapy, Monoclonal Antibodies, Gene Therapy
Abstract
Breast cancer is a condition where cells lose control and normal mechanisms, resulting in abnormal, fast and uncontrolled cell growth that occurs in the breast. Breast cancer is the most feared disease by women. One of the treatments is chemotherapy. The purpose of this study is to find out how the development of breast cancer chemotherapy treatment. As for the research method, this research uses literature review, in the search for literature sourced from 2 databases (Pubmed and Google Scholar) using keywords according to the theme. Where the results obtained show that chemotherapy treatment for breast cancer has developed where it has been found that monoclonal antibody therapy and gene therapy have been proven to increase disease-free expectations in breast cancer patients.References
[1] E. Elmika, “Gambaran Umur, dan Jenis Kelamin Pasien Kanker Payudara di RS Ibnu Sina Kota Makassar,” J. Penelit. Kesehat. Suara Forikes, vol. 11, no. 4, pp. 422–424, 2020.
[2] Kemenkes RI, “Kasus Kanker Payudara Paling Banyak Terjadi di Indonesia,” Databoks, p. 2019, 2019.
[3] S. Sarina, R. M. Thaha, and S. Nasir, “Faktor yang Berhubungan dengan Perilaku Sadari Sebagai Deteksi Dini Kanker Payudara pada Mahasiswi FKM Unhas,” Hasanuddin J. Public Heal., vol. 1, no. 1, pp. 61–70, 2020, doi: 10.30597/hjph.v1i1.9513.
[4] A. Rizka, M. K. Akbar, and N. A. Putri, “CARCINOMA MAMMAE SINISTRA T4bN2M1 METASTASIS PLEURA,” AVERROUS J. Kedokt. dan Kesehat. Malikussaleh, vol. 8, no. 1, p. 23, 2022, doi: 10.29103/averrous.v8i1.7006.
[5] Sumarni, Hartati, Supriyo, and A. S. Harnany, “Gambaran Tingkat Kecemasan Pasien Kanker Payudara Yang Menjalani Kemoterapi,” J. Lintas Keperawatan, vol. 43, p. 6, 2021, [Online]. Available: https://ejournal.poltekkes-smg.ac.id/ojs/index.php/LIK/article/view/9267
[6] J. P. Arisanti, N. Saptarina, and Y. D. Andarini, “Evaluasi Penggunaan Obat Kemoterapi Pada Penderita Kanker Payudara Di Rsup Dr. Seoradji Tirtonegoro Periode 2018,” Pharm. J. Islam. Pharm., vol. 4, no. 2, p. 1, 2020, doi: 10.21111/pharmasipha.v4i2.4960.
[7] W. Asmalinda, D. Setiawati, Jasmi, K. Khotimah, and E. Sapada, “Deteksi Dini Kanker Payudara Menggunakan Pemeriksaan Payudara Sendiri (SADARI),” J. Abdikemas, vol. 4, no. 1, pp. 10–17, 2022.
[8] Rasjidi, “Kemoterapi Kanker Ginekologi Dalam Praktik Sehari-Hari.” Sagung Set, Jakarta, 2014.
[9] Kks. Ganesh. N, Sharma, Rahul Dave, Jyotsana Sanadya, Pius Sharma, “VARIOUS TYPES AND MANAGEMENT OF BREAST CANCER: AN OVERVIEW,” J. Adv. Pharm. Tech. Res. Vol. 1 (2), Apr-Jun, 2010, vol. 1, no. 2, pp. 109–126, 2015.
[10] D. Firmana, “Keperawatan Kemoterapi.” Salemba medika, 2017.
[11] L. . Ulfa N.M, Kusuma, G.G., Zulfa, “Farmakologi-Farmakognosi Terapan Biji Pepaya Sebagai Alternatif Antikanker Payudara (Carcinoma Mamae).” 2018.
[12] P. N. Cahyawati, “Imunoterapi pada Kanker Payudara,” vol. 2, no. 1, 2018.
[13] R. L. B. Costa, “Clinical development of immunotherapies for HER2 + breast cancer : a review of HER2-directed monoclonal antibodies and beyond,” npj Breast Cancer, 2020, doi: 10.1038/s41523-020-0153-3.
[14] - Sugiharto, “Pendekatan Baru Terapi Kanker,” Medikora, no. 1, pp. 39–56, 2015, doi: 10.21831/medikora.v0i1.4753.
[15] C. A. Wijaya and M. Muchtaridi, “Pengobatan Kanker Melalui Metode Gen Terapi,” J. Farmaka, vol. 15, no. 1, pp. 53–68, 2017.
[2] Kemenkes RI, “Kasus Kanker Payudara Paling Banyak Terjadi di Indonesia,” Databoks, p. 2019, 2019.
[3] S. Sarina, R. M. Thaha, and S. Nasir, “Faktor yang Berhubungan dengan Perilaku Sadari Sebagai Deteksi Dini Kanker Payudara pada Mahasiswi FKM Unhas,” Hasanuddin J. Public Heal., vol. 1, no. 1, pp. 61–70, 2020, doi: 10.30597/hjph.v1i1.9513.
[4] A. Rizka, M. K. Akbar, and N. A. Putri, “CARCINOMA MAMMAE SINISTRA T4bN2M1 METASTASIS PLEURA,” AVERROUS J. Kedokt. dan Kesehat. Malikussaleh, vol. 8, no. 1, p. 23, 2022, doi: 10.29103/averrous.v8i1.7006.
[5] Sumarni, Hartati, Supriyo, and A. S. Harnany, “Gambaran Tingkat Kecemasan Pasien Kanker Payudara Yang Menjalani Kemoterapi,” J. Lintas Keperawatan, vol. 43, p. 6, 2021, [Online]. Available: https://ejournal.poltekkes-smg.ac.id/ojs/index.php/LIK/article/view/9267
[6] J. P. Arisanti, N. Saptarina, and Y. D. Andarini, “Evaluasi Penggunaan Obat Kemoterapi Pada Penderita Kanker Payudara Di Rsup Dr. Seoradji Tirtonegoro Periode 2018,” Pharm. J. Islam. Pharm., vol. 4, no. 2, p. 1, 2020, doi: 10.21111/pharmasipha.v4i2.4960.
[7] W. Asmalinda, D. Setiawati, Jasmi, K. Khotimah, and E. Sapada, “Deteksi Dini Kanker Payudara Menggunakan Pemeriksaan Payudara Sendiri (SADARI),” J. Abdikemas, vol. 4, no. 1, pp. 10–17, 2022.
[8] Rasjidi, “Kemoterapi Kanker Ginekologi Dalam Praktik Sehari-Hari.” Sagung Set, Jakarta, 2014.
[9] Kks. Ganesh. N, Sharma, Rahul Dave, Jyotsana Sanadya, Pius Sharma, “VARIOUS TYPES AND MANAGEMENT OF BREAST CANCER: AN OVERVIEW,” J. Adv. Pharm. Tech. Res. Vol. 1 (2), Apr-Jun, 2010, vol. 1, no. 2, pp. 109–126, 2015.
[10] D. Firmana, “Keperawatan Kemoterapi.” Salemba medika, 2017.
[11] L. . Ulfa N.M, Kusuma, G.G., Zulfa, “Farmakologi-Farmakognosi Terapan Biji Pepaya Sebagai Alternatif Antikanker Payudara (Carcinoma Mamae).” 2018.
[12] P. N. Cahyawati, “Imunoterapi pada Kanker Payudara,” vol. 2, no. 1, 2018.
[13] R. L. B. Costa, “Clinical development of immunotherapies for HER2 + breast cancer : a review of HER2-directed monoclonal antibodies and beyond,” npj Breast Cancer, 2020, doi: 10.1038/s41523-020-0153-3.
[14] - Sugiharto, “Pendekatan Baru Terapi Kanker,” Medikora, no. 1, pp. 39–56, 2015, doi: 10.21831/medikora.v0i1.4753.
[15] C. A. Wijaya and M. Muchtaridi, “Pengobatan Kanker Melalui Metode Gen Terapi,” J. Farmaka, vol. 15, no. 1, pp. 53–68, 2017.
